EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Doris K Hansen iD, Lauren C Peres iD, Danai Dima iD, Alicia Richards, Leyla Shune, Aimaz Afrough iD, Shonali Midha iD, Binod Dhakal iD, Mehmet H Kocoglu iD, Shebli Atrash iD, Christopher Ferreri, Omar Castaneda iD und 41 weitere

Journal of Clinical Oncology · 2025-05 · 43 (13) · 1597-1609

DOI: 10.1200/jco-24-01730 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Clinical Oncology, 2025-05. Verfasst von Doris K Hansen und 52 weiteren Autor:innen. Beteiligte Einrichtung: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Neoplasm Recurrence, Local, Antigens, CD19. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of patients with RRMM leukapheresed by December 31, 2022, with the intent to receive SOC ide-cel or cilta-cel at 19 institutions. An inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by therapy type. RESULTS A total of 641 patients were leukapheresed by December 31, 2022, with ide-cel (n = 386) and cilta-cel (n = 255). Five hundred eighty-six patients were infused (n = 350 for ide-cel; n = 236 for cilta-cel) with a median follow-up of 12.6 and 13.0 months for ide-cel and cilta-cel, respectively. After IPTW, patient characteristics were well balanced. Cilta-cel was associated with higher likelihood of grade ≥3 cytokine release syndrome (CRS; odds ratio [OR], 6.80 [95% CI, 2.28 to 20.33]), infections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3.56]), and delayed neurotoxicity (OR, 20.07 [95% CI, 4.46 to 90.20]). Cilta-cel was also associated with better treatment responses (≥complete response: OR, 2.42 [95% CI, 1.63 to 3.60]), longer progression-free survival (hazard ratio [HR], 0.48 [95% CI, 0.36 to 0.63]), and longer overall survival (HR, 0.67 [95% CI, 0.46 to 0.97]). No associations were observed between therapy type and immune effector cell–associated neurotoxicity syndrome, any CRS, severe cytopenia at days 30 and 90, or nonrelapse mortality. We observed consistent findings when repeating the analyses restricting the ide-cel cohort to patients infused during the same time period as Food and Drug Administration approval for cilta-cel (≥March 2022). CONCLUSION Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ide-cel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveNeoplasm Recurrence, LocalAntigens, CD19HumansMaleFemaleRetrospective StudiesMiddle AgedAgedStandard of CareAged, 80 and overAdultReceptors, Chimeric Antigen

Substanzen

idecabtagene vicleucelAntigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • University of Washington Fred Hutchinson Cancer Center, Seattle, WA.
  • University of Kansas Medical Center, Kansas City, KS.
  • Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, Dallas, TX.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Medical College of Wisconsin, Milwaukee, WI.

ORCID-Profile: Doris K Hansen, Lauren C Peres, Danai Dima, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H Kocoglu, Shebli Atrash, Omar Castaneda, James A Davis, Evguenia Bhurtel, Joseph McGuirk, Charlotte Wagner, Radhika Bansal, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Gurbakhash Kaur, Megan M Herr, Murali Janakiram, Ran Reshef, Douglas W Sborov, Faiz Anwer, Jack Khouri, Melissa Alsina, Frederick L Locke, Peter Voorhees, Larry D Anderson, Yi Lin, Krina K Patel, Surbhi Sidana

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Hansen, D. K., Peres, L. C., Dima, D., Richards, A., Shune, L., Afrough, A., Midha, S., Dhakal, B., Kocoglu, M. H., Atrash, S., Ferreri, C., Castaneda, O., Davis, J. A., Bhurtel, E., McGuirk, J., Wagner, C., Bansal, R., Costello, P., Smith, K., …, & US Multiple Myeloma Immunotherapy Consortium (2025). Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 43(13), 1597-1609. https://doi.org/10.1200/jco-24-01730

Vancouver

Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 2025;43(13):1597-1609. doi:10.1200/jco-24-01730

BibTeX
@article{Hansen2025,
  author = {Hansen, Doris K and Peres, Lauren C and Dima, Danai and Richards, Alicia and Shune, Leyla and Afrough, Aimaz and Midha, Shonali and Dhakal, Binod and Kocoglu, Mehmet H and Atrash, Shebli and Ferreri, Christopher and Castaneda, Omar and Davis, James A and Bhurtel, Evguenia and McGuirk, Joseph and Wagner, Charlotte and Bansal, Radhika and Costello, Patrick and Smith, Kinaya and Lieberman-Cribbin, Alex and De Avila, Gabriel and Purvey, Sneha and Hosoya, Hitomi and Mikkilineni, Lekha and Oswald, Laura B and Kaur, Gurbakhash and Pasvolsky, Oren and Gaballa, Mahmoud and Herr, Megan M and Forsberg, Peter and Janakiram, Murali and Htut, Myo and Asoori Maringanti, Sireesha and Kalariya, Nilesh and Hashmi, Hamza and Reshef, Ran and Sborov, Douglas W and Nadeem, Omar and Anwer, Faiz and Khouri, Jack and Raza, Shahzad and Atanackovic, Djordje and Alsina, Melissa and Freeman, Ciara L and Locke, Frederick L and Voorhees, Peter and Anderson, Larry D and Richard, Shambavi and Martin, Thomas and Lin, Yi and Patel, Krina K and Sidana, Surbhi and US Multiple Myeloma Immunotherapy Consortium, US Multiple Myeloma Immunotherapy Consortium},
  title = {Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {13},
  pages = {1597--1609},
  doi = {10.1200/jco-24-01730}
}
Kostenlos starten →